Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 26-29 January 2026

The European Medicines Agency's (EMA) human medicines committee, CHMP, recommended six new medicines for approval in January 2026. These recommendations include Fylrevy for hormone replacement therapy and Ilumira for radiolabelling purposes. Kayshild was recommended for treating metabolic dysfunction and Kygevvi for various paediatric and adult conditions. Supemtek, a trivalent influenza vaccine, also received a positive recommendation. The CHMP also recommended extending the therapeutic indications for several existing medicines. These include Akeega, Efmody, Eurneffy, Iclusig, Imfinzi, Kerendia, Noxafil, Opdivo, and Zynyz. Rezurock's re-examination resulted in a positive outcome. A referral procedure for Tavneos, a medicine for rare autoimmune diseases, was initiated. Additionally, updates were provided concerning Mounjaro and its use in treating heart conditions. The document provides crucial information on the outcome of EMA decisions on various medications. Several of the approved medicines, as well as the extended usage of others, showed positive outcomes.